MK-677 Reconstitution Calculator

No. MK-677 (ibutamoren) is an oral ghrelin receptor agonist/GH secretagogue that has been studied in humans, but the corpus does not show FDA approval for any routine indication (RCT/review). It remains a nonapproved performance-enhancing or investigational compound in many real-world settings, and it is frequently encountered in illicit or falsified products sold online or through supplement-style channels.

It reliably increases pulsatile GH secretion and raises IGF-1 in healthy older adults and in selected GH-deficient adults (human trials). In older adults it increased fat-free mass, but functional outcomes were mixed, and it did not clearly deliver a broad “anti-aging” benefit (RCT/review). In a hip-fracture recovery trial, some physical endpoints improved, but the program was also limited by safety concerns and incomplete functional benefit (RCT).

Community practice usually starts at 10 mg once daily, sometimes titrated to 25 mg/day, but these doses have not been clearly defined in the reviewed human trials (community protocol). Community practice usually starts lower—10 mg nightly, sometimes 12.5 mg, then titrates to 20–25 mg/day if tolerated (community protocol). Higher doses are more likely to worsen edema, appetite, and glucose control (RCT/review).

Either can work because MK-677 has a long enough action to raise GH/IGF-1 over 24 hours rather than acting like a brief injectable pulse (mechanistic/human). Night dosing is common because it may fit better with endogenous nocturnal GH physiology and some users prefer to place appetite increase and lethargy later in the day (practitioner consensus). If it causes daytime hunger or fatigue, evening use is usually more practical; if it disrupts sleep or causes vivid dreams, morning use may be easier (community protocol).

It is better described as an anabolic-support or weight-gain agent than a true fat-loss drug (RCT/review). In older adults it increased fat-free mass, but not necessarily performance to the same degree, and in some settings it can increase appetite substantially, which can drive body-weight gain from both lean and fat compartments (RCT). If calories are controlled and resistance training is present, users often pursue it for recovery, fullness, and lean-mass support rather than cutting (community protocol).

The most consistent issues are increased appetite, fluid retention/edema, transient insulin resistance or worsened glycemic control, and sometimes lethargy or paresthesias (RCT/review). A hip-fracture trial was stopped early because of a congestive heart failure safety signal, which makes fluid-sensitive populations a major concern (RCT). Real-world case literature also reports hepatotoxicity and a case of atraumatic splenic rupture in a user of multiple performance-enhancing agents including MK-677, although causality is uncertain and confounded (case report).

People with diabetes, prediabetes, edema, uncontrolled hypertension, heart failure risk, active cancer risk concerns, or significant liver disease should be particularly cautious because MK-677 can worsen glucose handling and fluid retention (RCT/review). Pregnancy and breastfeeding should be avoided because there are no adequate safety data in these populations (evidence gap; practitioner consensus). If you already have elevated fasting glucose, A1c, or unexplained liver enzyme abnormalities, baseline and follow-up labs are prudent (practitioner consensus).

Human studies in the corpus range from short-term dosing to months and up to about one year in some settings, but long-term safety for lifestyle/performance use is not established (RCT/review). Community use is often structured in 8–16 week blocks or 3–6 month runs with reassessment of edema, fasting glucose, A1c, and liver enzymes (community protocol). If appetite, numbness, edema, or glucose markers worsen meaningfully, continuing longer is hard to justify (practitioner consensus).

MK-677 is oral and stimulates endogenous GH secretion through the ghrelin receptor rather than replacing GH directly (human/mechanistic). Compared with injectable GH, it is simpler to use but less controllable, more hunger-promoting, and still carries insulin-resistance and edema liabilities (review). Compared with GHRP/GHRH peptide stacks, MK-677 is easier because it avoids injections, but it produces a more sustained signal rather than a pulse-based protocol (mechanistic/practitioner consensus).

Yes. Products sold as supplements or gray-market research compounds may contain the wrong drug, multiple undeclared drugs, or inaccurate doses (observational/review). MK-677 is also specifically discussed in anti-doping and forensic literature, including hair testing and sports-market surveillance, so athletes should assume detection is possible and sporting bodies may treat it as prohibited or suspicious (observational). For tested athletes, use is high risk from both an anti-doping and contamination standpoint.